— The first small molecule drug candidate showing ability to restore memory to normal in Alzheimer’s disease models — PITTSBURGH, Nov. 11, 2016 /PRNewswire/...

PITTSBURGH, Oct. 28, 2016 /PRNewswire/ — Cognition Therapeutics, Inc., a clinical stage neuroscience therapeutics company, announced today that Kenneth I. Moch has been...

PITTSBURGH, Sept. 29, 2016 /PRNewswire/ — Cognition Therapeutics Inc. (CogRx), a privately held, clinical stage pharmaceutical company focused on discovering and developing...

Scale Angels investee company Cognition Therapeutics commences clinical trials in Melbourne  Friday 18th September 2015. Cognition Therapeutics Inc. (CogRx), a privately held...